Trials / Unknown
UnknownNCT05889325
To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases
Efficacy and Safety of Irinotecan-eluting HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Unresectable Colorectal Liver Metastases
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Both drug-eluting bead transarterial chemoembolization (DEB-TACE) and hepatic arterial infusion chemotherapy (HAIC) are recommended for unresectable colorectal liver metastases (CRLM) treatment. However, the combined application of DEB-TACE and HAIC is not widely accepted. The aim of this single-center retrospective study was to evaluate the efficacy and safety of Irinotecan-eluting HepaSphere chemoembolization combined with HAIC for unresectable CRLM
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | DEB-TACE plus HAIC | the patients received HepaSphere DEB-TACE plus HAIC |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2023-09-01
- Completion
- 2023-11-01
- First posted
- 2023-06-05
- Last updated
- 2023-06-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05889325. Inclusion in this directory is not an endorsement.